The North American viral vector vaccines manufacturing market is expected to grow at a CAGR of 18.44% during the forecast period of 2019-2027. In the field of vaccines, viral vectors have shown promising results in human and veterinary pathogens that demand a broad spectrum of immune response from a host to gain control. The North America viral vector vaccine manufacturing market is primarily driven by the rising clinical trials in viral vectors and rising government funding in cancer research. Moreover, the high prevalence of genetic disorders and chronic diseases and government investment in gene-editing tools and research funding for gene research positively influence the growth of the viral vector vaccine manufacturing market in the North American region. As a result of this, the need for viral vector vaccines is expected to rise over the forecast period owing to the ongoing research activities to develop new advanced vaccines for diseases such as influenza and infectious diseases.

NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET FORECAST 2019-2027

North America Viral Vector Vaccines Manufacturing Market by Types 2019-2027 (Adenoviral Vectors, Retroviral Vectors, Lent Viral Vectors, Adeno-associated Viral Vectors, Poxvirus, Cytomegalovirus, Other Viral Vectors) by Application (Multivalent, Multipathogen) by Diseases (Human Diseases, Veterinary Diseases) by Geography.

Request free sample

Report Summary

The North American viral vector vaccines manufacturing market is expected to grow at a CAGR of 18.44% during the forecast period of 2019-2027. In the field of vaccines, viral vectors have shown promising results in human and veterinary pathogens that demand a broad spectrum of immune response from a host to gain control.

The North America viral vector vaccine manufacturing market is primarily driven by the rising clinical trials in viral vectors and rising government funding in cancer research. Moreover, the high prevalence of genetic disorders and chronic diseases and government investment in gene-editing tools and research funding for gene research positively influence the growth of the viral vector vaccine manufacturing market in the North American region. As a result of this, the need for viral vector vaccines is expected to rise over the forecast period owing to the ongoing research activities to develop new advanced vaccines for diseases such as influenza and infectious diseases. This is likely to boost the market growth in North America.

Top brands involved in the manufacturing of viral vector vaccines in North American are Cobra Biologics (Subsidiary of Recip Ab), Advanced Biotherapeutics Consulting, Applied Viromics, Batavia Biosciences, Biogen Idec (Now Biogen Inc.), Biovian, Cell And Gene Therapy Catapult, Brammer Bio, Ceva Corporate, Boehringer Ingelheim Gmbh, Advanced Bioscience Laboratories Inc., Benitec Biopharma, Ge Healthcare, Janssen Pharmaceutical Inc. and Id Pharma Co. Ltd.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • POX VIRUS CONSTITUTES THE LARGEST MARKET SHARE IN TERMS OF TYPES
        • HUMAN DISEASES ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
        • MULTIVALENT APPLICATIONS ARE WIDELY USED IN THE VIRAL VECTOR MANUFACTURING MARKET
    1. MARKET DETERMINANTS
      • MARKET DRIVERS
        • PROMISING RESULTS FROM SEVERAL CLINICAL STUDIES
        • MOUNTING NUMBER OF VIRAL VECTORS GENE-THERAPY-BASED CLINICAL TRIALS
        • GROWING CHRONIC DISEASES
      • MARKET OPPORTUNITIES
        • SWELLING INVESTMENT IN GENE-THERAPY-BASED R&D ACTIVITIES
        • INCREASE IN THE RESEARCH AND DEVELOPMENT
      • MARKET RESTRAINTS
        • POOR REIMBURSEMENT SYSTEM
        • STRINGENT GOVERNMENT POLICIES
      • MARKET CHALLENGES
        • UNFAVORABLE COMPENSATION SITUATION
        • PRICING PRESSURE COUPLED WITH LACK OF PRODUCT DIFFERENTIATION
        • RIGOROUS REGULATORY AGENDA
    1. MARKET SEGMENTATION
      • MARKET BY TYPES 2019-2027
        • ADENOVIRAL VECTORS
        • RETROVIRAL VECTORS
        • LENTIVIRAL VECTORS
        • ADENO-ASSOCIATED VIRAL VECTORS
        • POX VIRUS
        • CYTOMEGALOVIRUS
        • OTHER VIRAL VECTORS
      • MARKET BY APPLICATION 2019-2027
        • MULTIVALENT
        • MULTIPATHOGEN
      • MARKET BY DISEASES 2019-2027
        • HUMAN DISEASES
          • HEPATITIS
          • CANCER
          • MALARIA
          • TUBERCULOSIS
          • INFLUENZA
          • HIV
          • OTHER HUMAN DISEASES
        • VETERINARY DISEASES
          • AVIAN INFLUENZA
          • MAREK’S DISEASE
          • INFECTIOUS BRONCHITIS
          • PPR DISEASE
          • OTHER VETERINARY DISEASES
    1. KEY ANALYTICS
      • EVOLUTION AND TRANSITION
      • REGULATORY FRAMEWORK
        • THE UNITED STATES
      • KEY PROPERTIES OF VIRAL VECTOR
      • CHARACTERISTICS OF POTENTIAL VIRAL VACCINE VECTORS
      • PATENT ANALYSIS
        • THE UNITED STATES PATENT ANALYSIS
      • MANUFACTURING PROCESS OF A VIRAL-VECTOR
      • SMALL-SCALE MANUFACTURING PROCESS OF ADENOVIRUS
      • KEY SUPPLIERS IN VIRAL VECTOR MARKET
      • KEY BUYING CRITERIA
    2. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. COMPANY PROFILES
      • ADVANCED BIOTHERAPEUTICS CONSULTING
      • ADVANCED BIOSCIENCE LABORATORIES INC.
      • APPLIED VIROMICS
      • BATAVIA BIOSCIENCES
      • BENITEC BIOPHARMA
      • BIOGEN IDEC (NOW BIOGEN INC.)
      • BIOVIAN
      • BRAMMER BIO
      • BOEHRINGER INGELHEIM GMBH
      • CELL AND GENE THERAPY CATAPULT
      • CEVA CORPORATE
      • COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)
      • GE HEALTHCARE
      • JANSSEN PHARMACEUTICAL INC.
      • ID PHARMA CO. LTD

    LIST OF TABLES

    TABLE  1      NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)

    TABLE  2      ONGOING CLINICAL TRIALS RELATED TO VIRAL VECTORS

    TABLE  3      VARIOUS VIRAL VECTORS PROPERTIES AND THEIR APPLICATION IN GENE THERAPY

    TABLE  4      NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  5      KEY VIRAL VECTORS CHARACTERISTICS

    TABLE  6      NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENOVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  7      NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN RETROVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  8      ADVANTAGES AND DISADVANTAGES OF RETROVIRAL VECTORS

    TABLE  9      COMPONENTS OF HIV PROVIRUS

    TABLE  10    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN LENTIVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  11    SECOND- VS. THIRD-GENERATION LENTIVIRAL SYSTEMS

    TABLE  12    AAV VECTORS WITH THEIR TROPISMS AND RECEPTORS

    TABLE  13    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENO-ASSOCIATED VIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  14    LICENSED FOWL POX VIRAL-VECTORED VETERINARY VACCINES

    TABLE  15    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN POX VIRUS 2019-2027 ($ THOUSANDS)

    TABLE  16    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN CYTOMEGALOVIRUS 2019-2027 ($ THOUSANDS)

    TABLE  17    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN OTHER VIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  18    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET BY APPLICATION 2019-2027 ($ THOUSANDS)

    TABLE  19    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIVALENT 2019-2027 ($ THOUSANDS)

    TABLE  20    TB STATISTICS FOR 2016

    TABLE  21    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIPATHOGEN 2019-2027 ($ THOUSANDS)

    TABLE  22    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET BY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  23    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  24    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  25    NORTH AMERICA HUMAN DISEASES  MARKET IN HEPATITIS 2019-2027 ($ THOUSANDS)

    TABLE  26    ESTIMATED ACTUAL NEW CASES OF HAV

    TABLE  27    NORTH AMERICA HUMAN DISEASES  MARKET IN CANCER 2019-2027 ($ THOUSANDS)

    TABLE  28    ESTIMATED NEW CANCER CASES IN THE UNITED STATES 2017

    TABLE  29    NORTH AMERICA HUMAN DISEASES  MARKET IN MALARIA 2019-2027 ($ THOUSANDS)

    TABLE  30    MALARIA VACCINE DEVELOPMENT INITIATIVES

    TABLE  31    VIRAL VECTOR VACCINE CANDIDATES FOR TUBERCULOSIS

    TABLE  32    NORTH AMERICA HUMAN DISEASES  MARKET IN TUBERCULOSIS 2019-2027 ($ THOUSANDS)

    TABLE  33    NORTH AMERICA HUMAN DISEASES  MARKET IN INFLUENZA 2019-2027 ($ THOUSANDS)

    TABLE  34    BENEFITS AND CONCERN FOR VIRUS-VECTORED EXPERIMENTAL INFLUENZA VACCINES

    TABLE  35    NORTH AMERICA HUMAN DISEASES  MARKET IN HIV 2019-2027 ($ THOUSANDS)

    TABLE  36    NORTH AMERICA HUMAN DISEASES  MARKET IN OTHER HUMAN DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  37    ONGOING CLINICAL TRIALS AND DEVELOPMENT IN ZIKA VIRUS VACCINE

    TABLE  38    LICENSED VIRAL-VECTORED VETERINARY VACCINES

    TABLE  39    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  40    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES BY TYPES  2019-2027 ($ THOUSANDS)

    TABLE  41    AVIAN INFLUENZA VACCINES

    TABLE  42    NORTH AMERICA VETERINARY DISEASES MARKET IN AVIAN INFLUENZA 2019-2027 ($ THOUSANDS)

    TABLE  43    NORTH AMERICA VETERINARY DISEASES MARKET IN MAREK’S DISEASE 2019-2027 ($ THOUSANDS)

    TABLE  44    MAREK’S DISEASE VACCINES

    TABLE  45    NORTH AMERICA VETERINARY DISEASES MARKET IN INFECTIOUS BRONCHITIS 2019-2027 ($ THOUSANDS)

    TABLE  46    NORTH AMERICA VETERINARY DISEASES MARKET IN PPR DISEASE 2019-2027 ($ THOUSANDS)

    TABLE  47    NORTH AMERICA VETERINARY DISEASES MARKET IN OTHER VETERINARY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  48    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    TABLE  49    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    TABLE  50    FUNDING IN CANCER RESEARCH IN THE UNITED STATES ($ MILLIONS)

    TABLE  51    THE UNITED STATES  VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  52    NIH FUNDING FOR CRISPR-RELATED RESEARCH 2006-2016 ($)

    TABLE  53    CANADA VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

     

    LIST OF FIGURES

    FIGURE  1    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)

    FIGURE  2    SCHEMATIC OVERVIEW OF MULTIVALENT AND MULTIPATHOGEN VIRAL VECTOR VACCINES

    FIGURE  3    ESTIMATION OF PEOPLE LIVING WITH HIV 2016 (MILLION)

    FIGURE  4    PREVALENCE OF HBV INFECTION IN THE GENERAL POPULATION 2015 (MILLIONS)

    FIGURE  5    VACCINE ADVANCEMENTS TIMELINE

    FIGURE  6    STEPS REQUIREMENT FOR VACCINE APPROVAL

    FIGURE  7    VACCINE REVIEW AND REGULATION STEPS UNDER FDA

    FIGURE  8    MANUFACTURING PROCESS OF ADENOVIRUS

    FIGURE  9    THE UNITED STATES VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  10  CANADA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    Segmentation

    1. MARKET SEGMENTATION
      • MARKET BY TYPES 2019-2027
        • ADENOVIRAL VECTORS
        • RETROVIRAL VECTORS
        • LENTIVIRAL VECTORS
        • ADENO-ASSOCIATED VIRAL VECTORS
        • POXVIRUS
        • CYTOMEGALOVIRUS
        • OTHER VIRAL VECTORS
      • MARKET BY APPLICATION 2019-2027
        • MULTIVALENT
        • MULTIPATHOGEN
      • MARKET BY DISEASES 2019-2027
        • HUMAN DISEASES
          • HEPATITIS
          • CANCER
          • MALARIA
          • TUBERCULOSIS
          • INFLUENZA
          • HIV
          • OTHER HUMAN DISEASES
    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • THE UNITED STATES
        • CANADA

     

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      RELATED REPORTS